UroGen Pharma Ltd.URGNEarnings & Financial Report
UroGen Pharma Ltd. is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for urological diseases and specialty cancers. Its core offerings target unmet medical needs for conditions including non-muscle invasive bladder cancer, with primary operations and sales markets across North America and Europe.
URGN Q4 FY2025 Key Financial Metrics
Revenue
$37.8M
Gross Profit
$34.5M
Operating Profit
$-19.1M
Net Profit
N/A
Gross Margin
91.3%
Operating Margin
-50.5%
Net Margin
N/A
YoY Growth
54.0%
EPS
$-0.53
UroGen Pharma Ltd. Q4 FY2025 Financial Summary
UroGen Pharma Ltd. reported revenue of $37.8M (up 54.0% YoY) for Q4 FY2025, with a net profit of N/A (N/A margin). Cost of goods sold was $3.3M, operating expenses totaled $53.7M.
Key Financial Metrics
| Total Revenue | $37.8M |
|---|---|
| Net Profit | N/A |
| Gross Margin | 91.3% |
| Operating Margin | -50.5% |
| Report Period | Q4 FY2025 |
Revenue Breakdown
UroGen Pharma Ltd. Q4 FY2025 revenue of $37.8M breaks down across 2 segments, led by Jelmyto at $23.8M (62.9% of total).
| Segment | Revenue | % of Total |
|---|---|---|
| Jelmyto | $23.8M | 62.9% |
| Other | $14.0M | 37.1% |
UroGen Pharma Ltd. Revenue by Segment — Quarterly Trend
UroGen Pharma Ltd. revenue by segment across the last 4 reported quarters, showing how each business line (such as Jelmyto and Other) has evolved quarter over quarter.
| Segment | Q4 FY2025 | Q3 FY2025 | Q2 FY2025 | Q1 FY2025 |
|---|---|---|---|---|
| Jelmyto | $23.8M | $25.7M | $24.2M | $20.3M |
| Other | $14.0M | — | — | — |
UroGen Pharma Ltd. Annual Revenue by Year
UroGen Pharma Ltd. annual revenue history includes year-by-year totals (for example, 2025 revenue was $109.8M).
UroGen Pharma Ltd. Quarterly Revenue & Net Profit History
UroGen Pharma Ltd. results over the last 8 reported quarters, including revenue, net profit and year-over-year growth.
| Quarter | Revenue | Revenue YoY | Net Profit | Net Margin |
|---|---|---|---|---|
| Q4 FY2025 | $37.8M | +54.0% | N/A | N/A |
| Q3 FY2025 | $27.5M | +9.0% | $-33.3M | -121.3% |
| Q2 FY2025 | $24.2M | +10.8% | $-49.9M | -206.2% |
| Q1 FY2025 | $20.3M | +7.8% | $-43.8M | -216.5% |
| Q4 FY2024 | $24.6M | +4.4% | N/A | N/A |
| Q3 FY2024 | $25.2M | +20.9% | $-23.7M | -93.9% |
| Q2 FY2024 | $21.8M | +3.4% | $-33.4M | -152.9% |
| Q1 FY2024 | $18.8M | +9.2% | $-32.3M | -171.9% |
Income Statement
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $18.8M | $21.8M | $25.2M | $24.6M | $20.3M | $24.2M | $27.5M | $37.8M |
| YoY Growth | 9.2% | 3.4% | 20.9% | 4.4% | 7.8% | 10.8% | 9.0% | 54.0% |
Balance Sheet
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Assets | $200.6M | $281.8M | $301.9M | $285.7M | $247.6M | $208.7M | $185.0M | $200.5M |
| Liabilities | $240.7M | $251.5M | $276.4M | $294.5M | $294.1M | $302.1M | $300.5M | $305.9M |
| Equity | $-40.1M | $30.3M | $25.5M | $-8.8M | $-46.5M | $-93.4M | $-115.4M | $-105.5M |
Cash Flow
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Operating CF | $-31.7M | $-23.7M | $-27.7M | $-13.6M | $-42.0M | $-39.8M | $-42.3M | $-38.3M |